Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ClpP1P2 inhibitor (TB Alliance)
- Development stage
- Preclinical
- Lead developer
- TB Alliance
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The ClpP1P2 inhibitor program is a preclinical drug discovery initiative by the Global Alliance for TB Drug Development (TB Alliance) focused on developing small molecule inhibitors of the Caseinolytic protease P1/P2 (ClpP1P2) complex. ClpP1P2 is an essential, ATP-dependent serine protease in *Mycobacterium tuberculosis* that plays a critical role in protein degradation and the maintenance of cellular proteostasis. Inhibition of this enzyme complex leads to the toxic accumulation of misfolded proteins, resulting in bacterial cell death. This mechanism is distinct from existing TB therapies, potentially offering a new tool against drug-resistant strains. The program is currently in the lead optimization stage of preclinical development.
- Other names
- ClpP1P2 small molecule programClpP-1P2 small molecule programClpP 1P2 small molecule program
02
Targets
ClpP1/P2 (ClpP1/P2 protease complex)
Beyond the preview
Go deeper on ClpP1P2 inhibitor (TB Alliance).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ClpP1P2 inhibitor (TB Alliance).